GP和NP方案治疗晚期非小细胞肺癌的对照研究

目的：探讨吉西他滨联合顺铂（GP）及去甲长春花碱联合顺铂（NP）方案治疗晚期非小细胞肺癌的疗效及毒副反应。方法：晚期非小细胞肺癌30例以GP方案、27例以NP方案化疗，治疗2周期后评价疗效和不良反应。结果：有效率GP组46．7％，NP组为44．4％；中位生存期11．8个月和9．5个月；1年生存率为63．6％和59．1％，两组无统计学差异（P〉0．05），主要不良反应为血液学毒性。结论：GP和NP方案治疗晚期非小细胞肺癌的疗效肯定且相似，二者的不良反应可以耐受。

Efficacy comparison of GP regimen versus NP regimen in advanced non -small- cell lung cancer

Objective：To evaluate the efficacy and toxicity of gemcitabine combined with cisplatin （GP regimen） versus vinorelbine combined with cisplatin （NP regimen） in the treatment of advanced non -small -cell lung cancer （NSCLC）. Methods： Thirty cases with advanced NSCLC received GP, and twenty seven cases with advanced NSCLC received NP, the efficacy and toxicity were evaluated after two cycles. Results： The overall response rates of GP regimen group and NP regimen group were 46.7% and 44.4% respectively, and the median survival were 11.8 and 9.5 months respectively. There was no significant difference between two groups in response rate and median sur- vival. The major toxicity was hematological toxicity. Conclusion： The GP and NP regimen for advanced NSCLC were both effective and their effects were similar. The toxicity was tolerable.